Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Hematologic Neoplasms × tazemetostat × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 5 Prostatic Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Urinary Bladder Neoplasms 1 Sarcoma, Synovial 1 Sarcoma 1 Rhabdoid Tumor 1 Multiple Myeloma 1 Mesothelioma 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Hematologic Neoplasms 1 Chordoma 1 Carcinoma, Transitional Cell 1

Interventions

fludarabine 17 Cyclophosphamide 17 Whole-Body Irradiation 9 Tacrolimus 9 venetoclax 7 fludarabine phosphate 7 Sirolimus 7 Mycophenolic Acid 7 Azacitidine 6 Mesna 5 Bortezomib 5 Rituximab 4 Methotrexate 4 Dexamethasone 4 Busulfan 4 daratumumab 3 Stem Cell Transplantation 3 Peripheral Blood Stem Cell Transplantation 3 Melphalan 3 Lenalidomide 3 Filgrastim 3 Biopsy 3 Alemtuzumab 3 pomalidomide 2 merphos 2 ibrutinib 2 Thiotepa 2 Radiotherapy 2 Prednisone 2 Hematopoietic Stem Cell Transplantation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡